BenzingaOctober 22, 2026 at 10:06 AM NY5 Days Ago
Guggenheim Maintains Buy on Elevance Health, Raises Price Target to $485
Guggenheim analyst Jason Cassorla maintains Elevance Health (NYSE:ELV) with a Buy and raises the price target from $460 to $485.
What This Story Means
Claude is explaining the story in plain words…
Read the Full Story at the Source
The summary here comes from the news provider; the rest of the article lives on the publisher's site: Benzinga
